Skin
MULTI-001 Nivolumab v11
MULTI-002 Carboplatin and etoposide v1
MULTI-003 Pembrolizumab v12
MULTI-018 Larotrectinib v2
MULTI-019 Entrectinib v2
MULTI-020 Dabrafenib with Trametinib v3
MULTI-024 Avelumab v2
SKI-003 Vemurafenib v5
SKI-004 Ipilimumab v4
SKI-005 Vismodegib v3
SKI-009 Ipilimumab in combination with Nivolumab for metastatic melanoma v4
SKI-012 Talimogene laherparepvec v1
SKI-014 Encorafenib & Binimetinib v2
SKI-015 Cemiplimab v2
SKI-016 Opdualag® (nivolumab/relatlimab) v1
MULTI-002 Carboplatin and etoposide v1
MULTI-003 Pembrolizumab v12
MULTI-018 Larotrectinib v2
MULTI-019 Entrectinib v2
MULTI-020 Dabrafenib with Trametinib v3
MULTI-024 Avelumab v2
SKI-003 Vemurafenib v5
SKI-004 Ipilimumab v4
SKI-005 Vismodegib v3
SKI-009 Ipilimumab in combination with Nivolumab for metastatic melanoma v4
SKI-012 Talimogene laherparepvec v1
SKI-014 Encorafenib & Binimetinib v2
SKI-015 Cemiplimab v2
SKI-016 Opdualag® (nivolumab/relatlimab) v1